Current and developing methods of patient-controlled analgesia

Anesthesiology Clinics

Volumn 28, Issue 4, 2010, Pages 587-599

  Palmer, Pamela P ^a,b   Miller, Ronald D ^b  

^a AcelRx Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analgesia; Morphine; Opioid; Patient controlled; Postoperative; Sufentanil

Indexed keywords

AEROLEF; ALFENTANIL; BUPRENORPHINE; FENTANYL; HYDROMORPHONE; MORPHINE; OPIATE; PETHIDINE; RYLOMINE; SUFENTANIL; UNCLASSIFIED DRUG;

AGITATION; ANESTHESIST; CLINICAL TRIAL; CONFUSION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INFUSION; DRUG WITHDRAWAL; ERYTHEMA; HALLUCINATION; HEADACHE; HUMAN; INFUSION PUMP; INFUSION RATE; MEDICATION ERROR; NAUSEA AND VOMITING; NONHUMAN; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; PRESCRIPTION; PRURITUS; REGIONAL ANESTHESIA; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; URINE RETENTION; VASCULAR ACCESS;

ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; HUMANS; PAIN, POSTOPERATIVE;

EID: 78149478233     PISSN: 19322275     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anclin.2010.08.010     Document Type: Review

References (76)

1. Viscusi E.R. Patient-controlled drug delivery for acute postoperative pain management: a review of current and emerging technologies. Reg Anesth Pain Med 2008, 33:146-158.
2. Kaloul I., Guay J., Cote C., et al. The posterior lumbar plexus (psoas compartment) block and the three-in-one femoral nerve block provide similar postoperative analgesia after total knee replacement. Can J Anaesth 2004, 51:45-51.
3. White P.F., Kehlet H. Improving postoperative pain management: what are the unresolved issues?. Anesthesiology 2010, 112:220-225.
4. Sumida S., Lesley M.R., Hanna M.N., et al. Meta-analysis of the effect of extended-release epidural morphine versus intravenous patient-controlled analgesia on respiratory depression. J Opioid Manag 2009, 5:301-305.
5. Momeni M., Crucitti M., De K.M. Patient-controlled analgesia in the management of postoperative pain. Drugs 2006, 66:2321-2337.
6. Hudcova J., McNicol E., Quah C., et al. Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain. Cochrane Database Syst Rev 2006, 4:CD003348.
7. Ballantyne J.C., Carr D.B., Chalmers T.C., et al. Postoperative patient-controlled analgesia: meta-analyses of initial randomized control trials. J Clin Anesth 1993, 5:182-193.
8. Macintyre P.E. Safety and efficacy of patient-controlled analgesia. Br J Anaesth 2001, 87:36-46.
9. Institute for Safe Medication Practices Medication safety alert. High alert medication feature: reducing patient harm from opiates Available at:, Accessed May 20, 2010. http://www.ismp.org/Newsletters/acutecare/articles/20070222.asp.
10. Panchal S.J., Damaraju C.V., Nelson W.W., et al. System-related events and analgesic gaps during postoperative pain management with the fentanyl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia. Anesth Analg 2007, 105:1437-1441.
11. Webster J., Osborne S., Rickard C., et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev 2010, 3:CD007798.
12. Wheeler M., Oderda G.M., Ashburn M.A., et al. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain 2002, 3:159-180.
13. Hutchison R.W., Chon E.H., Tucker W.F., et al. A comparison of a fentanyl, morphine, and hydromorphone patient-controlled intravenous delivery for acute postoperative analgesia: a multicenter study of opioid-induced adverse reactions. Hosp Pharm 2006, 41:659-663.
14. Simopoulos T.T., Smith H.S., Peeters-Asdourian C., et al. Use of meperidine in patient-controlled analgesia and the development of a normeperidine toxic reaction. Arch Surg 2002, 137:84-88.
15. American Pain Society Principles of analgesic use in the treatment of acute pain and cancer pain 2008, American Pain Society, Glenview (IL). 6th edition.
16. Owen H., Plummer J.L., Armstrong I., et al. Variables of patient-controlled analgesia. 1. Bolus size. Anaesthesia 1989, 44:7-10.
17. Hagle M.E., Lehr V.T., Brubakken K., et al. Respiratory depression in adult patients with intravenous patient-controlled analgesia. Orthop Nurs 2004, 23:18-27.
18. Schug S.A., Torrie J.J. Safety assessment of postoperative pain management by an acute pain service. Pain 1993, 55:387-391.
19. Sidebotham D., Dijkhuizen M.R., Schug S.A. The safety and utilization of patient-controlled analgesia. J Pain Symptom Manage 1997, 14:202-209.
20. American Pain Society Principles of analgesic use in the treatment of acute pain and cancer pain 2003, American Pain Society, Glenview (IL), p.1-73. 5th edition.
21. Abbott P.C.A. Plus II patient-controlled analgesic pumps prone to misprogramming resulting in narcotic overinfusions. Health Devices 1997, 26:389-391.
22. Vicente K.J., Kada-Bekhaled K., Hillel G., et al. Programming errors contribute to death from patient-controlled analgesia: case report and estimate of probability. Can J Anesth 2003, 50:328-332.
23. Keohane C.A., Hayes J., Saniuk C., et al. Intravenous medication safety and smart infusion systems: lessons learned and future opportunities. J Infus Nurs 2005, 28:321-328.
24. Rothschild J.M., Keohane C.A., Cook E.F., et al. A controlled trial of smart infusion pumps to improve medication safety in critically ill patients. Crit Care Med 2005, 33:533-540.
25. Center for Devices and Radiological Health, US Food and Drug Administration. Infusion Pump Improvement Initiative. April 2010.
26. Meissner B., Nelson W., Hicks R., et al. The rate and costs attributable to intravenous patient-controlled analgesia errors. Hosp Pharm 2009, 44:312-324.
27. Choiniere M., Rittenhouse B.E., Perreault S., et al. Efficacy and costs of patient-controlled analgesia versus regularly administered intramuscular opioid therapy. Anesthesiology 1998, 89:1377-1388.
28. Hutchison R.W., Anastassopoulos K., Vallow S., et al. Intravenous patient-controlled analgesia pump and reservoir logistics: results from a multicenter questionnaire. Hosp Pharm 2007, 42:1036-1044.
29. Bonnet F., Eberhart L., Wennberg E., et al. Fentanyl HCl iontophoretic transdermal system versus morphine IV-PCA for postoperative pain management: survey of healthcare provider opinion. Curr Med Res Opin 2009, 25:293-301.
30. Evans C., Schein J., Nelson W., et al. Improving patient and nurse outcomes: a comparison of nurse tasks and time associated with two patient-controlled analgesia modalities using delphi panels. Pain Manag Nurs 2007, 8:86-95.
31. Macintyre P.E., Jarvis D.A. Age is the best predictor of postoperative morphine requirements. Pain 1996, 64:357-364.
32. Miaskowski C. Patient-controlled modalities for acute postoperative pain management. J Perianesth Nurs 2005, 20:255-267.
33. Cashman J.N., Dolin S.J. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 2004, 93:212-223.
34. Leung J.M., Sands L.P., Paul S., et al. Does postoperative delirium limit the use of patient-controlled analgesia in older surgical patients?. Anesthesiology 2009, 111:625-631.
35. Macintyre P.E. Intravenous patient-controlled analgesia: one size does not fit all. Anesthesiol Clin North America 2005, 23:109-123.
36. Dolin S.J., Cashman J.N. Tolerability of acute postoperative pain management: nausea, vomiting, sedation, pruritis, and urinary retention. Evidence from published data. Br J Anaesth 2005, 95:584-591.
37. Mather L.E. Opioids: a pharmacologist's delight!. Clin Exp Pharmacol Physiol 1995, 22:833-836.
38. Ratka A., Wittwer E., Baker L., et al. Pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in healthy older men and women. Am J Pain Manag 2004, 14:45-55.
39. Sear J.W., Hand C.W., Moore R.A., et al. Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. Br J Anaesth 1989, 62:22-27.
40. Sear J.W., Hand C.W., Moore R.A., et al. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Br J Anaesth 1989, 62:28-32.
41. Baker L., Hyrien O., Ratka A. Contributions of morphine-3-glucuronide and morphine-6-glucuronide to differences in morphine analgesia in humans. Am J Pain Manag 2003, 13:16-28.
42. Grass J.A. Patient-controlled analgesia. Anesth Analg 2005, 101:S44-S61.
43. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002, 1:CD003447.
44. Hong D., Flood P., Diaz G. The side effects of morphine and hydromorphone patient-controlled analgesia. Anesth Analg 2008, 107:1384-1389.
45. Cepeda M.S., Farrar J.T., Baumgarten M., et al. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003, 74:102-112.
46. Camu F., Van Aken H., Bovill J.G. Postoperative analgesic effects of three demand-dose sizes of fentanyl administered by patient-controlled analgesia. Anesth Analg 1998, 87:890-895.
47. Prakash S., Fatima T., Pawar M. Patient-controlled analgesia with fentanyl for burn dressing changes. Anesth Analg 2004, 99:552-555.
48. Egan T.D., Lemmens H.J., Fiset P., et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 1993, 79:881-892.
49. Hughes M.A., Glass P.S., Jacobs J.R. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992, 76:334-341.
50. Ved S.A., Dubois M., Carron H., et al. Sufentanil and alfentanil pattern of consumption during patient-controlled analgesia: a comparison with morphine. Clin J Pain 1989, 5(Suppl 1):S63-S70.
51. 2O in patients without cardiac disease undergoing general surgery. Anesthesiology 1987, 66:130-135.
52. Bailey P.L., Streisand J.B., East K.A., et al. Differences in magnitude and duration of opioid-induced respiratory depression and analgesia with fentanyl and sufentanil. Anesth Analg 1990, 70:8-15.
53. De Castro J. Practical applications and limitations of analgesic anesthesia: a review. Acta Anaesthesiol Belg 1976, 27:107-128.
54. Monk J.P., Beresford R., WardSufentanil A. A review of its pharmacological properties and therapeutic use. Drugs 1988, 36:286-313.
55. Savoia G., Loreto M., Gravino E. Sufentanil: an overview of its use for acute pain management. Minerva Anestesiol 2001, 67:206-216.
56. Brusset A., Levron J.C., Olivier P., et al. Comparative pharmacokinetic study of fentanyl and sufentanil after single high-bolus doses. Clin Drug Invest 1999, 18:377-389.
57. Stoeckel H., Schuttler J., Magnussen H., et al. Plasma fentanyl concentrations and the occurrence of respiratory depression in volunteers. Br J Anaesth 1982, 54:1087-1095.
58. Becker L.D., Paulson B.A., Miller R.D., et al. Biphasic respiratory depression after fentanyldroperidol or fentanyl alone used to supplement nitrous oxide anesthesia. Anesthesiology 1976, 44:291-296.
59. Power I. Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain. Br J Anaesth 2007, 98:4-11.
60. IONSYS™ (fentanyl iontophoretic trandermal system) [package insert] 2006, Ortho-McNeil, Inc, Raritan, NJ, Available at:, Accessed June 20, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021338lbl.pdf.
61. Viscusi E.R., Reynolds L., Chung F., et al. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA 2004, 291:1333-1341.
62. European Medicines Agency Evaluation of medicines for human use. Questions and answers on the recommendation to suspend the marketing authorisation of Ionsys Available at:, Accessed May 21, 2010. http://www.ema.europa.eu/humandocs/PDFs/EPAR/ionsys/Ionsys_Q%26A_60985608en.pdf.
63. Palmer PP, Hamel LG, Skowronski RJ. Single- and repeat-dose pharmacokinetics of sublingual sufentanil NanoTab in healthy volunteers [abstract A1222]. Presented at: the Annual Meeting of the American Society of Anesthesiologists. New Orleans (LA), October 17-21, 2009.
64. Griffin DW, Skowronski RJ, Dasu BN, et al. A phase 2 open-label functionality, safety, and efficacy study of the sufentanil NanoTab™ PCA System in patients following elective unilateral knee replacement surgery. Poster presented at: the 35th Annual Spring Meeting and Workshops of the American Society of Regional Anesthesia and Pain Medicine. Toronto, Ontario, Canada, April 22-25, 2010.
65. Minkowitz HS, Skowronski RJ, Palmer PP. A phase 2 multicenter, randomized, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of sublingual sufentanil NanoTab™ in patients following elective unilateral knee replacement surgery. Poster presented at: the 35th Annual Spring Meeting and Workshops of the American Society of Regional Anesthesia and Pain Medicine. Toronto, Ontario (Canada), April 22-25, 2010.
66. Singla NK, Skowronski RJ, Palmer PP. A phase 2 multicenter, randomized, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of sublingual sufentanil NanoTab™ in patients following major abdominal surgery. Poster presented at: the 35th Annual Spring Meeting and Workshops of the American Society of Regional Anesthesia and Pain Medicine. Toronto, Ontario (Canada), April 22-25, 2010.
67. Thipphawong J.B., Babul N., Morishige R.J., et al. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 2003, 99:693-700.
68. Brull R, Chan V, University Health Network TWTO. A randomized controlled trial demonstrates the efficacy, safety and tolerability of Aerosolized Free and Liposome-Encapsulated Fentanyl (AeroLEF) via pulmonary administration. Poster presented at the American Pain Society (APS) Annual Meeting. Tampa (FL), May 8-10, 2008.
69. Clark A, Rossiter-Rooney M, Valle-Leutri F, et al. Aerosolized Liposome-Encapsulated Fentanyl (AeroLEF™) via pulmonary administration allows patients with moderate to severe post-surgical acute pain to self-titrate to effective analgesia. Presented at the American Pain Society 2008 Annual Meeting. Tampa (FL), May 8-10, 2008.
70. Vadivelu N., Mitra S., Narayan D. Recent advances in postoperative pain management. Yale J Biol Med 2010, 83:11-25.
71. Stoker D.G., Reber K.R., Waltzman L.S., et al. Analgesic efficacy and safety of morphine-chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med 2008, 9:3-12.
72. Toussaint S., Maidl J., Schwagmeier R., et al. Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief. Can J Anesth 2000, 47:299-302.
73. Heshmati F., Noroozinia H., Abbasivash R., et al. Intranasal sufentanil for postoperative pain control in lower abdominal pediatric surgery. Ir J Pharmacol Ther 2006, 5:131-133.
74. Mathieu N., Cnudde N., Engelman E., et al. Intranasal sufentanil is effective for postoperative analgesia in adults. Can J Anaesth 2006, 53:60-66.
75. Dale O., Hjortkjaer R., Kharasch E.D. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002, 46:759-770.
76. Rosati J., Gallagher M., Shook B., et al. Evaluation of an oral patient-controlled analgesia device for pain management in oncology inpatients. J Support Oncol 2007, 5:443-448.